PubRank

Seitaro Mutoh

Author PubWeight™ 59.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 2004 1.64
2 Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002 1.17
3 Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol 2008 1.11
4 Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett 2005 0.96
5 Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003 0.95
6 Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003 0.95
7 Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol 2005 0.95
8 Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005 0.92
9 Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol 2007 0.91
10 Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol 2010 0.91
11 Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat. Biol Pharm Bull 2007 0.91
12 FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Cytokine 2005 0.91
13 Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 2004 0.90
14 Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol 2003 0.89
15 A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Pharmacol Exp Ther 2004 0.89
16 FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol 2005 0.89
17 Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. Eur J Pharmacol 2005 0.88
18 FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur J Pharmacol 2005 0.88
19 Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys. J Pharmacol Sci 2008 0.86
20 Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003 0.86
21 Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res 2004 0.86
22 Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol 2004 0.86
23 FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator. J Cereb Blood Flow Metab 2005 0.86
24 Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp Neurol 2006 0.85
25 Temporal and topographic profiles of tissue hypoxia following transient focal cerebral ischemia in rats. J Vet Med Sci 2006 0.85
26 Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007 0.85
27 Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci 2005 0.84
28 A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther 2006 0.84
29 Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther 2004 0.83
30 FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation. Int Immunopharmacol 2005 0.83
31 FK1706, a novel non-immunosuppressant neurophilin ligand, ameliorates motor dysfunction following spinal cord injury through its neuroregenerative action. Eur J Pharmacol 2008 0.83
32 Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 2003 0.83
33 Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. Biol Pharm Bull 2006 0.83
34 A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J Pharmacol Exp Ther 2004 0.82
35 Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J Cereb Blood Flow Metab 2003 0.82
36 Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci 2004 0.82
37 Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol Pharm Bull 2008 0.82
38 Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur J Pharmacol 2005 0.81
39 Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist. J Neurotrauma 2005 0.81
40 Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 2003 0.81
41 Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol 2009 0.81
42 Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats. Eur J Pharmacol 2003 0.81
43 FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 2005 0.81
44 Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. Brain Res 2008 0.80
45 Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. Eur J Pharmacol 2005 0.80
46 Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int Immunopharmacol 2007 0.80
47 Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 2005 0.80
48 Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure. Nephrol Dial Transplant 2005 0.80
49 Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 2002 0.80
50 Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats. Brain Res 2008 0.78
51 Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. Biochem Pharmacol 2011 0.78
52 Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations. Microbiol Immunol 2007 0.78
53 Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole. Microbiol Immunol 2006 0.78
54 Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats. Eur J Pharmacol 2002 0.78
55 FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells. Int Immunopharmacol 2005 0.78
56 Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci 2006 0.78
57 ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats. Acta Diabetol 2009 0.78
58 FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban. J Cereb Blood Flow Metab 2005 0.77
59 Contribution of tachykinin receptor subtypes to micturition reflex in guinea pigs. Eur J Pharmacol 2003 0.77
60 Blockade of the antinociceptive effect of spinally administered kyotorphin by naltrindole in mice. Neurosci Lett 2002 0.77
61 Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats. Eur J Pharmacol 2003 0.77
62 Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology (Berl) 2004 0.77
63 FR143166 attenuates spinal pain transmission through activation of the serotonergic system. Eur J Pharmacol 2002 0.77
64 Acute and chronic effects of FR-149175, a beta 3-adrenergic receptor agonist, on energy expenditure in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 2004 0.76
65 The spinal antinociceptive effect of kyotorphin in mice: involvement of the descending noradrenergic and serotonergic systems. Neurosci Lett 2002 0.76
66 Topical application of FK506 (tacrolimus) ointment inhibits mite antigen-induced dermatitis by local action in NC/Nga mice. Int Arch Allergy Immunol 2004 0.76
67 FK506 aerosol locally inhibits antigen-induced airway inflammation in Guinea pigs. Int Arch Allergy Immunol 2005 0.76
68 Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. Pharmacol Biochem Behav 2002 0.76
69 Diphenidol has no actual broad antiemetic activity in dogs and ferrets. J Pharmacol Sci 2004 0.76
70 A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet. Eur J Pharmacol 2004 0.76
71 Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav 2002 0.75
72 Choleretic actions of insulin-like growth factor-I, prednisolone, and ursodeoxycholic acid in rats. Dig Dis Sci 2003 0.75
73 Effect of FK3657, a non-peptide bradykinin B2 receptor antagonist, on allergic airway disease models. Eur J Pharmacol 2003 0.75
74 FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. Neuropharmacology 2008 0.75
75 Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig. Eur J Pharmacol 2004 0.75
76 Effect of systemic FR140423, a new analgesic compound, in a rat model of postoperative pain: contribution of delta-opioid receptors. Neurosci Lett 2003 0.75
77 Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. J Pharmacol Exp Ther 2003 0.75
78 Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia. Biol Pharm Bull 2008 0.75
79 Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons. J Pharmacol Exp Ther 2003 0.75
80 Possible involvement of enhanced intestinal microsomal triglyceride transfer protein (MTP) gene expression in acceleration of lipid absorption by a western-type diet in apolipoprotein E knockout mice. Life Sci 2004 0.75
81 Insulin-like growth factor-I prevents lethal acute liver failure induced by D-galactosamine and lipopolysaccharide in rats. In Vivo 2003 0.75
82 Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats. Pharmacol Res 2009 0.75
83 FR177391, a new anti-hyperlipidemic agent from Serratia. II. Pharmacological activity of FR177391. J Antibiot (Tokyo) 2005 0.75